|Title:||Identification and characterisation of new compounds to treat chronic bacterial lung infections|
|Publisher:||University of Sydney.|
Infectious Diseases and Immunology.
Central Clinical School - RPAH.
|Abstract:||Drug resistance is a major concern in the treatment of numerous diseases caused by infectious agents, creating an urgent need for new treatments. In this study, I assessed the effectiveness of compounds against two medically important lung pathogens, Mycobacterium tuberculosis and Pseudomonas aeruginosa, using complementary methods of drug discovery and assessment. The first approach identified high-affinity iron chelators of the pyridoxal isonicotinoyl hydrazone (PIH) class that could restrict the growth of clinically significant mycobacteria, using both in vitro and in vivo infection models. In a second study, novel chemical scaffolds, termed metal-cyclam complexes (MCyC), were found to be specifically active against pathogenic mycobacteria, displayed relatively low toxicity and in some cases displayed a synergistic effect with currently used treatments. The final study used high-throughput screening assays to identify a small subset of compounds that could inhibit the growth of Pseudomonas and mycobacterial species, from a library of 1920 compounds made up of a diverse series of natural and synthetic products. In conclusion, this thesis has identified lead products that with additional study/modification could lead to viable compounds for future treatment of pathogenic bacterial infection in humans.|
|Type of Work:||PhD Doctorate|
|Type of Publication:||Doctor of Philosophy Ph.D.|
|Appears in Collections:||Sydney Digital Theses (Open Access)|
|ELLIS Samantha - Final thesis.pdf||PhD Thesis||4.19 MB||Adobe PDF|
Items in Sydney eScholarship Repository are protected by copyright, with all rights reserved, unless otherwise indicated.